Ammar Al-Chalabi

Industry partners are vital collaborators in our mission to find crucial new treatments for #MND/#ALS.

Our co-director, @ammaralchalabi.bsky.social, teamed up with Raya Therapeutics at TRICALS to lead a discussion on Repurposing and Combination Therapies.

Read more 👇

ukmndri.org/2025/11/13/r...

Annual Stephen Hawking MND Lecture The Annual Stephen Hawking MND Lectures were launched 2017 – and are now and established and important part of the Association’s calendar.

Do you want to know about #ALS #MND genetics? Are you affected directly or indirectly by ALS MND or working as a scientist or clinician in this area?

I was honoured to give the Hawking Lecture this year and it's now freely available to view.

www.mndassociation.org/professional...

Genetic Testing: What People Need to Make Informed Decisions A new study reveals what people with MND need when deciding on genetic testing, including clear information and tailored support.

New research reveals what people with #MND/#ALS need when deciding on genetic testing: clear info, implications for family & tailored support.📃

This data can help inform decision aids to assist people when thinking about genetic testing.

Read more🔗

ukmndri.org/2025/12/03/g...

🚨 Final Call for the £7.5m (~$10m) Longitude Prize on ALS. Don’t miss your chance to make a real difference for those living with #ALS (the most common form of #MND).

Submit your application by 15:00 GMT (10:00 AM EST) tomorrow!

Apply here: bit.ly/4nyp6nq

⏰1 week to go! Entries to the £7.5M (~$10M) Longitude Prize on ALS are closing next week – submit your application before Wednesday 3rd December 2025.

Your expertise could make the difference.

🔗Learn more and apply today: bit.ly/4nyp6nq

@ohenews.bsky.social estimates that eradicating ALS could deliver $143B+ in value over 10 years. The potential global value is huge. #ALS and #MND remain underfunded and breakthroughs are urgently needed.

Full report: lnkd.in/e3-DMaiB
Learn more about the Prize bit.ly/4nyp6nq

🚨 Only 2 weeks left to apply! The £7.5M (~$10M) Longitude Prize on ALS is closing soon – submit your application before 3 December 2025 and don’t miss your chance to make a real difference.

🔗 To learn more about the Prize, click here: bit.ly/4nyp6nq

Covid-19 Boosters in the UK – Statement Covid-19 Boosters in the UK – Statement This autumn is the first since the Joint Committee on Vaccination and Immunisation (JCVI) changed its policy on who can receive Covid-19 vaccination bo…

People with #ALS #MND with respiratory compromise should be offered COVID immunization by their GPs.

united2endmnd.org/2025/11/14/c...

Repurposed Drugs: Accelerating MND Treatment Discovery Discover how repurposed drugs are helping accelerate the search for effective treatments for MND through innovative UK research.

Drug development is a complex and costly process.

By using medicines approved for other conditions, we can overcome barriers in drug development.

Read our blog explaining why we believe repurposed drugs could help us find new treatments for #MND/#ALS.

ukmndri.org/2025/11/13/r...

Yesterday, we attended @mndoddie5.bsky.social's Discovery Network Showcase 2025.

Researchers, clinicians, industry partners, and people affected by #MND/#ALS discussed how the network can drive forward progress in better understanding MND and the development of new treatments.

Our Co-Director, Prof. @ammaralchalabi.bsky.social, gave a fantastic talk yesterday, hosted by @mndassoc.bsky.social, on #MND/#ALS genetics, why they matter and how discoveries are shaping new treatments.

Thank you to everyone who joined in person & online!
#MNDresearch #genetics

We had the pleasure of catching up with Dr Brian Dickie MBE (@bd365.bsky.social), Chief Scientist at the @mndassoc.bsky.social, the principal funder of the £7.5M Longitude Prize on ALS.

📖 Read the full Q&A here: bit.ly/3KTi1Ap

Join us at the #ASHG25 Annual Meeting in Boston, starting today!

Visit us at Booth 46, we’d love to meet you and discuss how the ~$10M Longitude Prize on ALS is harnessing #AI to transform the future of neurodegenerative disease treatment.

@challengeworks.bsky.social @geneticssociety.bsky.social

Lewis Moody: Former England captain reveals motor neurone disease diagnosis Former England captain Lewis Moody reveals he has been diagnosed with motor neurone disease in an exclusive BBC interview.

We must find an effective treatment for #ALS #MND

@ukmndri.bsky.social

BBC News - Former England captain Moody reveals MND diagnosis
www.bbc.com/sport/rugby-...

⏰ 2 months to go until applications close for the £7.5 million Longitude Prize on ALS.

You could help transform treatment for neurodegenerative diseases like hashtag #ALS, the most common form of motor neurone disease ( #MND ).

Learn more: bit.ly/4mlzSg5

Connect with us at #NealsMtg ! We are thrilled to be joining the NEALS meeting once again in person this coming week. For anyone impacted by ALS virtual registration is free. Cheers to NEALS for such an open policy. See more at https://meeting.neals.org/ . #EndtheLegacy #NEALS

The biological evidence from changes in blood that the disease process starts years before symptoms matters for understanding risk factors and disease mechanisms. It is also important in clinic when people ask if an operation or injury caused their illness if in fact the process started years before

Yes!

A plasma proteomics-based candidate biomarker panel predictive of amyotrophic lateral sclerosis - Nature Medicine Plasma proteomic analysis of presymptomatic individuals with amyotrophic lateral sclerosis identifies novel disease-associated proteins and enables the development of an accurate diagnostic biomarker ...

This is a landmark paper showing a predictive test for #ALS #MND up to 40 years before onset and able to predict age of onset. Huge implications

www.nature.com/articles/s41...

🌍 Be part of the global effort to tackle #ALS.

The £7.5m (~$10m) #LongitudePrizeOnALS is searching for innovators in #AI, #data, #biotech, and #neurology.

🧠 Meet the teams already registered, and find out how you can partner with them below.

🔗https://bit.ly/4mdHxxX

Longitude Prize launched to accelerate AI-driven drug discovery A new international challenge prize has been launched to transform drug discovery for ALS, the most common form of MND through AI.

🧠 The @ukmndri.bsky.social is an #MND powerhouse, accelerating progress towards new treatments and, ultimately, a cure.

Read their article about how the #LongitudePrizeOnALS could be a game-changer for drug discovery in neurodegenerative diseases.

🔗 bit.ly/40Tmmsh

@ammaralchalabi.bsky.social

Postdoc Research Assistant: Investigating C9ORF72 Postdoc Research Assistant in Dr Arpan Mehta’s lab at University of Dundee, using CRISPR screens in iPSC-derived motor neurons to study ALS mechanisms.

Postdoc Research Assistant in Dr Arpan Mehta’s lab at University of Dundee, using CRISPR screens in iPSC-derived motor neurons to study ALS mechanisms. Closing date: 4th August

www.dementiaresearcher.nihr.ac.uk/job/postdoc-...

Climbing the ALS mountain Mike Rogers, MND Association Director of Research and Innovation, looks at how data and AI could unlock new treatments.

“MND is one of the most scientifically and biologically challenging diseases to tackle. That said, no mountain is insurmountable…”

Dr. Mike Rogers (@mndassoc.bsky.social) shares why the #LongitudePrizeOnALS is key to creating new opportunities for #ALS & #MND

📰 longevity.technology/news/climbin...

Tagging 🧪 🧬🖥️

Could sleep changes signal the early stages of MND or FTD? Research has found that disrupted sleep may offer some clues to possible early warning signs of the ALS or FTD.

New research has examined how disrupted sleep patterns may signal the early stages of #MND / #ALS or FTD, providing clues to earlier detection.

Read more ⬇️
🔗 ukmndri.org/2025/07/16/r...

This post is part of our Research Snapshot series, powered by Readable Research at @sheffielduni.bsky.social

Structural variants in the 3D genome as drivers of disease - Nature Reviews Genetics Disruption of the 3D genome caused by structural variation contributes to developmental disorders and cancer. The authors review the causes and molecular and clinical consequences of position effects arising from disruptions to the genome architecture.

Researchers reveal that structural variants disrupting the 3D genome can drive diseases like cancer by altering gene expression.

by Sreenivasan VKA, Yumiceba V and Spielmann M in Nat Rev Genet #MedSky

👉 get more here

📖 read the article:

⏰ Reminder: Our first Welcome Webinar is tomorrow, Tuesday 9th of July at 09:00 BST.

💻 Register below to learn everything you need to know about the #LongitudePrizeOnALS, including how to apply, how the Prize works, and what support is available.

Research Fellow: Glial-immune crosstalk and sporadic ALS Research Fellow vacancy at UCL MND Centre. Join Prof Andrea Malaspina’s team to study immune responses & neoantigens in ALS using proteomics & cell phenotyping

Research Fellow vacancy at UCL MND Centre. Join Prof Andrea Malaspina’s team to study immune responses and neoantigens in ALS using proteomics and cell phenotyping. Closing date: 20th July

www.dementiaresearcher.nihr.ac.uk/job/research...

🧠 As the principal funder, the @mndassoc.bsky.social has been instrumental in bringing the #LongitudePrizeOnALS to life.

We were joined by Dr Usman Khan last week, who spoke on the power of cross-specialism collaboration.

Learn more about the Prize: bit.ly/4kD3tSh

#AIforGood #MND #ALS

Want to learn more about the £7.5M #LongitudePrizeOnALS?
Join one of our welcome webinars to find out how the Prize works and how to get involved.

Register here:
📅 9 July, 09:00 BST: bit.ly/4nzJuWA
📅 10 July, 17:00 BST: bit.ly/3Tl4u5u

#AIForGood #MND #ALS